131 related articles for article (PubMed ID: 30806848)
1. Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma.
Beinse G; Hulin A; Rousseau B
Invest New Drugs; 2019 Dec; 37(6):1289-1291. PubMed ID: 30806848
[TBL] [Abstract][Full Text] [Related]
2. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.
Fukudo M; Tamaki G; Azumi M; Kakizaki H; Matsumoto S; Tasaki Y
Invest New Drugs; 2021 Apr; 39(2):595-604. PubMed ID: 33098047
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
Henriksen JN; Andersen CU; Fristrup N
Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
[TBL] [Abstract][Full Text] [Related]
4. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma.
Rini BI; Melichar B; Fishman MN; Oya M; Pithavala YK; Chen Y; Bair AH; Grünwald V
Ann Oncol; 2015 Jul; 26(7):1372-7. PubMed ID: 25701454
[TBL] [Abstract][Full Text] [Related]
5. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
[TBL] [Abstract][Full Text] [Related]
6. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R; Inoue T; Fujiyama N; Tsuchiya N; Numakura K; Kagaya H; Saito M; Narita S; Satoh S; Niioka T; Miura M; Habuchi T
Med Oncol; 2018 Mar; 35(4):51. PubMed ID: 29524031
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Osawa T; Kojima T; Hara T; Sugimoto M; Eto M; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Miyauchi Y; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Tamura K; Komiyama M; Goto T; Yokomizo A; Kohei N; Kashiwagi A; Murakami M; Sazuka T; Yasumoto H; Iwamoto H; Mitsuzuka K; Morooka D; Shimazui T; Yamamoto Y; Ikeshiro S; Nakagomi H; Morita K; Tomida R; Mochizuki T; Inoue T; Kitamura H; Yamada S; Ito YM; Murai S; Nishiyama H; Shinohara N;
Cancer Sci; 2020 Jul; 111(7):2460-2471. PubMed ID: 32402135
[TBL] [Abstract][Full Text] [Related]
9. Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.
Miura Y; Imamura CK; Uchino K; Kishida T; Matsubara N; Shinojima T; Kondo K; Hongo F; Yoshimura K; Tanigawara Y; Takano T
Clin Genitourin Cancer; 2019 Feb; 17(1):e1-e11. PubMed ID: 30529389
[TBL] [Abstract][Full Text] [Related]
10. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.
Tomita Y; Uemura H; Oya M; Shinohara N; Habuchi T; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Rini BI
BMC Cancer; 2019 Jan; 19(1):17. PubMed ID: 30616534
[TBL] [Abstract][Full Text] [Related]
11. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
[TBL] [Abstract][Full Text] [Related]
12. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
13. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
14. Axitinib, a new therapeutic option in renal cell carcinoma.
Kessler ER; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2012 Oct; 48(10):633-44. PubMed ID: 23110259
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma.
Yamamoto Y; Otori T; Inoue R; Yano S; Hirata H; Matsumoto H; Matsuyama K; Matsuyama H
J Clin Pharmacol; 2020 Feb; 60(2):256-263. PubMed ID: 31538342
[TBL] [Abstract][Full Text] [Related]
16. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A; Orillard E; Mouillet G; Calcagno F; Devillard N; Bouchet S; Royer B
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1273-1276. PubMed ID: 28451830
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma.
Miyake H; Harada K; Ozono S; Fujisawa M
Med Oncol; 2016 Aug; 33(8):95. PubMed ID: 27444960
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
20. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
